All of the following are GpIIb/IIIa antagonists, except?
Enalapril increases the level of which of the following?
Which of the following prostaglandin analogs is used in glaucoma?
Which of the following statements regarding ACE inhibitors is TRUE?
A hypertensive patient is suffering from bilateral renal artery stenosis. Which of the following drugs should not be given?
At a dose concentration of <2 mcg/kg/min, dopamine predominantly acts on which receptors?
All of the following drugs are useful for long-term treatment of congestive heart failure except?
Nitroglycerine exerts beneficial effects in classical angina pectoris primarily by:
What is the drug of choice for the management of acute pulmonary edema?
Combination use of beta-blockers and calcium channel blockers can cause all of the following except:
Explanation: **Explanation:** The question asks to identify the drug that is **not** a Glycoprotein (Gp) IIb/IIIa antagonist. **1. Why Clopidogrel is the correct answer:** Clopidogrel belongs to the **P2Y12 receptor inhibitors** (Thienopyridines) class. It works by irreversibly blocking the ADP receptor on the platelet surface, preventing the activation of the GpIIb/IIIa receptor complex. While it ultimately inhibits the same pathway, it is not a direct antagonist of the GpIIb/IIIa receptor itself. **2. Analysis of incorrect options (Direct GpIIb/IIIa Antagonists):** These drugs are the "final common pathway" inhibitors of platelet aggregation, as they block the binding of fibrinogen to the GpIIb/IIIa receptor. * **Abciximab:** A chimeric monoclonal antibody fragment. It is non-competitive and has a long biological half-life. * **Tirofiban:** A non-peptide, small-molecule mimetic. It is a reversible, competitive antagonist. * **Eptifibatide:** A cyclic peptide derived from rattlesnake venom (Barbourin). It is also a reversible, competitive antagonist. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** GpIIb/IIIa inhibitors prevent the cross-linking of platelets by fibrinogen, which is the final step in platelet aggregation. * **Route of Administration:** All GpIIb/IIIa inhibitors are administered **intravenously (IV)** only. * **Clinical Use:** Primarily used in Acute Coronary Syndrome (ACS) and during Percutaneous Coronary Intervention (PCI). * **Side Effect:** The most significant side effect is **bleeding** and **thrombocytopenia** (especially with Abciximab). * **Mnemonic:** To remember GpIIb/IIIa inhibitors, use **"TEA"** (**T**irofiban, **E**ptifibatide, **A**bciximab).
Explanation: ### Explanation **Correct Option: C (Bradykinin)** **Mechanism:** Enalapril is an **Angiotensin-Converting Enzyme (ACE) Inhibitor**. The ACE enzyme (also known as Kininase II) has a dual function in the body: 1. It converts Angiotensin I to Angiotensin II (a potent vasoconstrictor). 2. It degrades **Bradykinin** (a potent vasodilator) into inactive metabolites. By inhibiting ACE, Enalapril prevents the breakdown of Bradykinin, leading to its accumulation in the tissues and blood. **Why the other options are incorrect:** * **A & B (Interferon and Growth factors):** ACE inhibitors do not have a direct or clinically significant effect on the systemic levels of interferons or growth factors. While ACE inhibitors may indirectly influence tissue remodeling (e.g., reducing cardiac hypertrophy), they do not "increase" these specific molecules as a primary pharmacological action. --- ### High-Yield Clinical Pearls for NEET-PG: * **The "Dry Cough" Connection:** The accumulation of Bradykinin and Substance P in the lungs is the primary cause of the characteristic **dry, hacking cough** seen in 5–20% of patients on ACE inhibitors. * **Angioedema:** Increased Bradykinin levels are also responsible for the rare but life-threatening side effect of angioedema. * **Switching Therapy:** If a patient develops a cough due to Enalapril, the best next step is to switch them to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not inhibit Kininase II and thus do not increase Bradykinin. * **Active Form:** Remember that Enalapril is a **prodrug**; it must be converted by hepatic esterases into its active metabolite, **Enalaprilat**. (Lisinopril and Captopril are the exceptions—they are not prodrugs).
Explanation: ### Explanation **Correct Answer: B. Latanoprost** **Mechanism and Clinical Use:** Latanoprost is a **PGF2α analog** used as a first-line agent in the management of **Open-Angle Glaucoma**. It works by increasing the **uveoscleral outflow** of aqueous humor, thereby reducing intraocular pressure (IOP). Unlike traditional beta-blockers, it is administered once daily at night, offering superior efficacy and patient compliance. **Analysis of Incorrect Options:** * **A. Misoprostol:** A PGE1 analog primarily used for the prevention of NSAID-induced gastric ulcers and for medical abortion (in combination with mifepristone) due to its potent uterine contraction properties. * **C. Enprostil & D. Rioprostil:** These are PGE2 analogs that were developed as anti-secretory agents to treat peptic ulcer disease. They are rarely used in modern clinical practice compared to Proton Pump Inhibitors (PPIs). **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of Latanoprost:** The most characteristic side effects are **increased brown pigmentation of the iris**, thickening/darkening of eyelashes (trichomegaly), and occasional conjunctival hyperemia. * **Other Glaucoma Prostaglandins:** Bimatoprost, Travoprost, and Tafluprost. * **Bimatoprost Note:** It is also FDA-approved for the treatment of eyelash hypotrichosis. * **Contraindication:** Prostaglandin analogs should be avoided in patients with active intraocular inflammation (uveitis) or cystoid macular edema.
Explanation: **Explanation:** **1. Why Option B is Correct:** The most significant side effect of the first dose of an ACE inhibitor (ACEi) is **"First-dose hypotension."** Patients who are volume-depleted—specifically those on **diuretics**—have a highly activated Renin-Angiotensin-Aldosterone System (RAAS). When an ACEi is introduced, it causes a sudden, profound drop in Angiotensin II levels, leading to significant vasodilation and postural hypotension. To mitigate this risk, it is standard clinical practice to **omit or stop the diuretic dose for 24–48 hours** before initiating ACE inhibitor therapy. **2. Why the Other Options are Incorrect:** * **Option A:** ACE inhibitors inhibit the **Angiotensin-Converting Enzyme (ACE)**, which converts Angiotensin I to Angiotensin II. The conversion of Angiotensinogen to Angiotensin I is inhibited by **Aliskiren** (a Direct Renin Inhibitor). * **Option C:** **Lisinopril** is a long-acting ACE inhibitor with a half-life that allows for once-daily dosing. In contrast, **Enalapril** has a shorter duration of action and is a prodrug (converted to Enalaprilat), whereas Lisinopril is active as such. * **Option D:** ACE inhibitors are actually the **drugs of choice** in diabetic patients. They provide **nephroprotection** by dilating the efferent arteriole, reducing intraglomerular pressure, and decreasing albuminuria. **Clinical Pearls for NEET-PG:** * **Teratogenicity:** ACE inhibitors are contraindicated in pregnancy (cause fetal renal anomalies/hypoplasia). * **Side Effects Mnemonic (CAPTOPRIL):** **C**ough (due to Bradykinin), **A**ngioedema, **P**roteinuria, **T**aste changes, **O**thostatic hypotension, **P**regnancy contraindication, **R**enal artery stenosis (bilateral) contraindication, **I**ncreased potassium (**Hyperkalemia**), **L**eukopenia. * **Bilateral Renal Artery Stenosis:** ACE inhibitors can precipitate acute renal failure in these patients because Angiotensin II is required to maintain GFR by constricting the efferent arteriole.
Explanation: **Explanation:** **Why Enalapril is the Correct Answer:** In patients with **bilateral renal artery stenosis (RAS)**, the renal perfusion pressure is significantly reduced. To maintain an adequate Glomerular Filtration Rate (GFR), the body relies on the **Renin-Angiotensin-Aldosterone System (RAAS)**. Specifically, Angiotensin II causes **vasoconstriction of the efferent arteriole**, which creates the necessary back-pressure to maintain filtration. **Enalapril**, an ACE inhibitor, blocks the formation of Angiotensin II. This leads to efferent arteriolar vasodilation, a sudden drop in intraglomerular pressure, and a subsequent precipitous fall in GFR, potentially leading to **acute renal failure**. Therefore, ACE inhibitors (and ARBs) are strictly contraindicated in bilateral RAS (or unilateral RAS in a solitary kidney). **Why Other Options are Incorrect:** * **B. Atenolol:** A beta-blocker that reduces blood pressure primarily by decreasing cardiac output and renin release. While it affects the RAAS, it does not cause the acute hemodynamic collapse of GFR seen with ACE inhibitors. * **C. Nifedipine:** A Calcium Channel Blocker (CCB) that acts as a peripheral vasodilator. It does not interfere with the efferent arteriolar tone and is generally considered safe in RAS. * **D. Hydrochlorothiazide:** A thiazide diuretic that reduces BP by decreasing blood volume. It does not have a specific adverse hemodynamic effect on the stenosed renal vasculature. **NEET-PG High-Yield Pearls:** * **Goldblatt Kidney:** The experimental model for renovascular hypertension. * **Diagnostic Clue:** Suspect RAS if a patient’s serum creatinine rises by **>30%** after starting an ACE inhibitor or ARB. * **Drug of Choice:** While ACE inhibitors are contraindicated in *bilateral* RAS, they are often the drug of choice for *unilateral* RAS (where the healthy kidney can compensate), provided renal function is monitored closely.
Explanation: Dopamine is a unique catecholamine because its pharmacological effects are **dose-dependent**, a concept frequently tested in NEET-PG. ### **Explanation of the Correct Answer** At **low doses (<2 mcg/kg/min)**, dopamine acts selectively on **D1 (Dopaminergic) receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of these receptors leads to vasodilation, which increases renal blood flow and promotes natriuresis (sodium excretion). This is often referred to as the "renal dose," though its clinical utility in preventing renal failure is now debated. ### **Analysis of Incorrect Options** * **Option A (Beta-1 receptors):** These are stimulated at **intermediate doses (2–10 mcg/kg/min)**. At this range, dopamine increases cardiac contractility (inotropy) and heart rate (chronotropy), making it useful in cardiogenic shock. * **Option C (Alpha-1 receptors):** These are stimulated at **high doses (>10 mcg/kg/min)**. At this level, the alpha-adrenergic effects override the dopaminergic effects, leading to systemic vasoconstriction and increased peripheral vascular resistance (used in distributive shock). ### **High-Yield Clinical Pearls for NEET-PG** * **Dopamine vs. Dobutamine:** While dopamine has dose-dependent alpha/beta/D1 effects, **Dobutamine** is a relatively selective **Beta-1 agonist** used primarily for heart failure and cardiogenic shock. * **Fenoldopam:** This is a selective **D1 receptor agonist** used intravenously for the management of hypertensive emergencies, as it maintains renal perfusion while lowering blood pressure. * **Incompatibility:** Dopamine should never be mixed with alkaline solutions (like Sodium Bicarbonate) in the same IV line, as it will be inactivated.
Explanation: ### Explanation The management of Congestive Heart Failure (CHF) is divided into drugs that improve long-term survival and those used for acute stabilization. **1. Why Dobutamine is the Correct Answer:** Dobutamine is a **selective $\beta_1$ agonist** with potent positive inotropic effects. It is administered via continuous intravenous infusion and has a very short half-life (approx. 2 minutes). Due to its parenteral route, risk of arrhythmias, and the development of tolerance (tachyphylaxis), it is strictly reserved for **acute decompensated heart failure** or cardiogenic shock. It is **not** suitable for long-term outpatient management. **2. Why the other options are incorrect:** * **Ramipril (ACE Inhibitor):** These are first-line drugs for chronic CHF. They inhibit cardiac remodeling and are proven to **decrease mortality**. * **Spironolactone (Aldosterone Antagonist):** Used in NYHA Class II-IV heart failure, it prevents myocardial fibrosis and significantly **reduces mortality and morbidity**. * **Digoxin (Cardiac Glycoside):** While it does not reduce mortality, it is used in long-term management to **reduce hospitalization rates** and control symptoms, especially in patients with co-existing atrial fibrillation. **Clinical Pearls for NEET-PG:** * **Mortality-Reducing Drugs in CHF:** ACE inhibitors, ARBs, Beta-blockers (Carvedilol, Metoprolol, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Drugs that DO NOT reduce mortality:** Digoxin, Furosemide, and Dobutamine. * **Dobutamine vs. Dopamine:** Dobutamine is preferred in heart failure because it increases cardiac output with less increase in heart rate and peripheral resistance compared to dopamine.
Explanation: **Explanation:** **Mechanism of Action (The Correct Answer):** Nitroglycerine (NTG) is a potent venodilator. At therapeutic doses, it acts primarily on the large peripheral veins, increasing venous capacitance. This leads to **peripheral pooling of blood**, which decreases venous return to the heart. The resulting **reduction in cardiac preload** (Left Ventricular End-Diastolic Pressure) decreases ventricular wall tension and myocardial oxygen demand. Since angina occurs due to an imbalance between oxygen supply and demand, reducing the demand is the primary mechanism for relieving pain in classical angina. **Analysis of Incorrect Options:** * **Option A:** While NTG can dilate coronary arteries, it does not significantly increase *total* coronary blood flow in patients with atherosclerotic (classical) angina, as those vessels are often already maximally dilated by local metabolites. * **Option B:** NTG does redistribute blood flow from epicardial to **vulnerable subendocardial regions** by reducing LV wall tension, but this is secondary to the reduction in preload. * **Option D:** NTG only reduces afterload (arteriolar dilation) at high doses. Its primary clinical effect at standard doses is on the venous side (preload). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** NTG is the DOC for acute anginal attacks (Sublingual route due to high first-pass metabolism). * **Tolerance:** Continuous use leads to "tachyphylaxis" (depletion of free -SH groups). A **10-12 hour nitrate-free interval** is required daily. * **Monday Disease:** Workers in explosive factories develop tolerance during the week but lose it over the weekend, leading to headaches and tachycardia upon returning on Monday. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can cause life-threatening hypotension.
Explanation: **Explanation:** **Furosemide** is the drug of choice for acute pulmonary edema due to its unique dual mechanism of action. When administered intravenously, it provides immediate relief through **venodilation** (mediated by prostaglandin release), which increases venous capacitance and reduces preload even before the onset of diuresis [2]. This is followed by a potent **diuretic effect** (inhibition of Na+/K+/2Cl- cotransporter in the thick ascending limb of Henle), which reduces total body fluid volume and further alleviates pulmonary congestion [2]. **Why the other options are incorrect:** * **Hydrochlorothiazide:** This is a thiazide diuretic acting on the distal convoluted tubule. It is less potent than loop diuretics and lacks the rapid venodilatory effect required in emergency settings [2]. * **Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist). It has a slow onset of action (taking days to reach peak effect) and is used for long-term mortality benefit in chronic heart failure, not acute management. * **Triamterene:** This is a direct ENaC inhibitor (potassium-sparing). Like spironolactone, its diuretic potency is too weak for the rapid fluid mobilization needed in pulmonary edema. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Acute Pulmonary Edema:** **LMNOP** (L-Lasix/Furosemide, M-Morphine, N-Nitrates, O-Oxygen, P-Position/Propped up). * **Side Effects of Furosemide:** Hypokalemia, Ototoxicity (especially at high doses), Hyperuricemia, and Hypocalcemia (unlike Thiazides which cause Hypercalcemia) [2]. * **Sulfonamide Allergy:** Furosemide is a sulfonamide derivative [2]; in case of severe allergy, **Ethacrynic acid** is the alternative loop diuretic [1].
Explanation: ### Explanation The combination of **Beta-blockers (BBs)** and **Calcium Channel Blockers (CCBs)**, particularly the non-dihydropyridines like Verapamil and Diltiazem, results in synergistic depressant effects on the heart. **1. Why Hypertension is the Correct Answer (The "Except"):** Beta-blockers and CCBs both act to reduce blood pressure. Beta-blockers decrease cardiac output and renin release, while CCBs cause peripheral vasodilation and decrease cardiac contractility. Therefore, their combined use leads to **hypotension**, not hypertension. Using them together to treat hypertension requires extreme caution due to the risk of additive adverse effects on cardiac conduction. **2. Analysis of Incorrect Options:** * **Bradycardia & Heart Block:** Both BBs and non-dihydropyridine CCBs (Verapamil > Diltiazem) are **negative chronotropes** (decrease heart rate) and **negative dromotropes** (slow AV conduction). When used together, they can cause profound sinus bradycardia or precipitate high-grade AV block. * **Hypotension:** As both drug classes reduce the force of contraction (**negative inotropy**) and/or systemic vascular resistance, a significant drop in blood pressure is a common and expected side effect of the combination. **Clinical Pearls for NEET-PG:** * **The "Verapamil Rule":** Intravenous Verapamil is strictly contraindicated in patients already taking Beta-blockers due to the high risk of **asystole** or complete cardiovascular collapse. * **Safe Combination:** If a CCB must be added to a Beta-blocker, a **Dihydropyridine** (e.g., Amlodipine) is preferred because it has minimal effect on the SA/AV nodes and primarily acts on vascular smooth muscle. * **Drug of Choice:** Beta-blockers are the preferred treatment for CCB overdose (specifically for managing the resulting hyperglycemia and hypotension).
Antihypertensive Agents
Practice Questions
Drugs for Heart Failure
Practice Questions
Antiarrhythmic Drugs
Practice Questions
Antianginal Agents
Practice Questions
Lipid-Lowering Drugs
Practice Questions
Anticoagulants and Antiplatelet Drugs
Practice Questions
Thrombolytic Agents
Practice Questions
Drugs Used in Pulmonary Hypertension
Practice Questions
Drugs Used in Shock
Practice Questions
Cardiovascular Effects of Non-Cardiovascular Drugs
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free